Cabaletta Bio Inc (NASDAQ: CABA)’s stock price has dropped by -11.29 in relation to previous closing price of 2.69. Nevertheless, the company has seen a gain of 5.12% in its stock price over the last five trading days. seekingalpha.com reported 2025-01-06 that Cabaletta Bio, Inc.’s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough cash to operate for 5–6 quarters, assuming no further expense growth or additional financing. Risks include the aggressive nature of CAR T-cell therapy for non-life-threatening diseases and competition from other cell therapy approaches.
Is It Worth Investing in Cabaletta Bio Inc (NASDAQ: CABA) Right Now?
The 36-month beta value for CABA is also noteworthy at 2.46. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for CABA is 41.37M, and at present, short sellers hold a 15.05% of that float. The average trading volume of CABA on January 08, 2025 was 2.41M shares.
CABA’s Market Performance
CABA’s stock has seen a 5.12% increase for the week, with a -27.58% drop in the past month and a -45.02% fall in the past quarter. The volatility ratio for the week is 10.49%, and the volatility levels for the past 30 days are at 10.07% for Cabaletta Bio Inc The simple moving average for the last 20 days is -5.66% for CABA’s stock, with a simple moving average of -67.03% for the last 200 days.
Analysts’ Opinion of CABA
Many brokerage firms have already submitted their reports for CABA stocks, with Evercore ISI repeating the rating for CABA by listing it as a “In-line.” The predicted price for CABA in the upcoming period, according to Evercore ISI is $6 based on the research report published on December 20, 2024 of the previous year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see CABA reach a price target of $6, previously predicting the price at $12. The rating they have provided for CABA stocks is “Equal Weight” according to the report published on December 19th, 2024.
UBS gave a rating of “Buy” to CABA, setting the target price at $10 in the report published on October 10th of the previous year.
CABA Trading at -23.06% from the 50-Day Moving Average
After a stumble in the market that brought CABA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.94% of loss for the given period.
Volatility was left at 10.07%, however, over the last 30 days, the volatility rate increased by 10.49%, as shares sank -23.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.39% lower at present.
During the last 5 trading sessions, CABA rose by +4.85%, which changed the moving average for the period of 200-days by -86.34% in comparison to the 20-day moving average, which settled at $2.53. In addition, Cabaletta Bio Inc saw 5.12% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CABA starting from Binder Gwendolyn, who sale 11,000 shares at the price of $19.59 back on Jan 19 ’24. After this action, Binder Gwendolyn now owns 20,000 shares of Cabaletta Bio Inc, valued at $215,439 using the latest closing price.
Stock Fundamentals for CABA
Current profitability levels for the company are sitting at:
- -28.55 for the present operating margin
- 0.71 for the gross margin
The net margin for Cabaletta Bio Inc stands at -25.98. The total capital return value is set at -0.63. Equity return is now at value -62.16, with -55.16 for asset returns.
Currently, EBITDA for the company is -73.23 million with net debt to EBITDA at 1.38. When we switch over and look at the enterprise to sales, we see a ratio of -9.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.11.
Conclusion
In summary, Cabaletta Bio Inc (CABA) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
